Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...144145146147148149150151152153154...401402»
  • ||||||||||  Review, Journal:  Sarcopenia and bone health: new acquisitions for a firm liaison. (Pubmed Central) -  Dec 6, 2022   
    New therapeutic strategies that simultaneously target bone and muscle tissue are limited, but recently new targets for the development of dual-action drug therapies have been identified. This narrative review aims to provide an overview of the latest scientific evidence associated with OS, a complex disorder that will pave the way for future research aimed at understanding the bone-muscle-associated pathogenetic mechanisms.
  • ||||||||||  Journal:  Editorial: Muscle mass and function in COVID-19. (Pubmed Central) -  Dec 6, 2022   
    In conclusion, pre-treatment low muscle quality is a strong prognostic indicator of death risk in patients affected by HNC and undergoing (chemo)radiotherapy with curative intent. No abstract available
  • ||||||||||  Review, Journal:  Nascent to novel methods to evaluate malnutrition and frailty in the surgical patient. (Pubmed Central) -  Dec 6, 2022   
    Finally, the evaluation of nutrition risk and status is essential to predict and mitigate surgical outcomes. Nascent to novel approaches are the future of objectively identifying patients at perioperative nutrition risk and guiding therapy toward optimal perioperative standards of care.
  • ||||||||||  Journal:  Sarcopenia: the 'hidden' marker of surgical outcome. (Pubmed Central) -  Dec 6, 2022   
    Nascent to novel approaches are the future of objectively identifying patients at perioperative nutrition risk and guiding therapy toward optimal perioperative standards of care. No abstract available
  • ||||||||||  Journal:  Body composition in sarcopenia in middle-aged individuals (Pubmed Central) -  Dec 6, 2022   
    No abstract available the introduction of bioimpedancemetry and dynamometry into early screening for muscle mass reduction will allow timely start of therapeutic and preventive measures even in middle age, which will lead to a decrease in the progression of sarcopenia in the elderly, as well as improve the quality of life.
  • ||||||||||  Journal:  Response letter to "sarcopenia, osteoporosis and fractures: what we see". (Pubmed Central) -  Dec 6, 2022   
    the introduction of bioimpedancemetry and dynamometry into early screening for muscle mass reduction will allow timely start of therapeutic and preventive measures even in middle age, which will lead to a decrease in the progression of sarcopenia in the elderly, as well as improve the quality of life. No abstract available
  • ||||||||||  Journal:  C-reactive protein and muscle-related measures over 14 years in Chinese community-dwelling older adults. (Pubmed Central) -  Dec 6, 2022   
    Ingestion of low-protein foods and high-protein foods is infrequently associated with sarcopenia and ingestion of high-protein foods. This prospective study suggests that, among Chinese community-dwelling older adults, baseline inflammatory state as measured by hsCRP was not associated with the decline in muscle-related measures over a long period of time.
  • ||||||||||  Journal:  A post-middle-age crisis for CD47 and THBS1 that turns into a vicious cycle. (Pubmed Central) -  Dec 4, 2022   
    report on alterations in CD47 and THBS1 expression and function in aged muscle stem cells that disrupt their regeneration capacity. Targeting THBS1-CD47 cross-signaling is sufficient to reverse sarcopenia and restore muscle mass and function in aged mice.
  • ||||||||||  Journal:  Frail patients dropping out of neoadjuvant treatment: what should we do? (Pubmed Central) -  Dec 4, 2022   
    Even though not significant, survival rates for patients who interrupted treatment in the whole trial were lower (5-year OS completed 64.6 vs. interrupted 41.8 p 0.07). Promptness in giving patient support for gastrointestinal symptoms, careful evaluation of anemia and patient nutritional status, and psychological programs from the beginning of the oncologic treatment may improve the final results.
  • ||||||||||  Journal:  Combined assessment of muscle quality and quantity predicts oncological outcome in patients with esophageal cancer. (Pubmed Central) -  Dec 4, 2022   
    Promptness in giving patient support for gastrointestinal symptoms, careful evaluation of anemia and patient nutritional status, and psychological programs from the beginning of the oncologic treatment may improve the final results. Combined assessment between preoperative PMI and mIMAC could stratify risk for oncological outcomes, and preoperative mIMAC might be surrogate marker for aging and nutritional status in esophageal cancer patients.
  • ||||||||||  Journal:  Chest X-ray-based opportunistic screening of sarcopenia using deep learning. (Pubmed Central) -  Dec 3, 2022   
    Combined assessment between preoperative PMI and mIMAC could stratify risk for oncological outcomes, and preoperative mIMAC might be surrogate marker for aging and nutritional status in esophageal cancer patients. Chest X-ray-based deep leaning model improved detection of sarcopenia, which merits further investigation.
  • ||||||||||  Preclinical, Journal:  Effects of an exogenous ketone ester using multi-omics in skeletal muscle of aging C57BL/6J male mice. (Pubmed Central) -  Dec 3, 2022   
    In conclusion, 72-week-old male mice consuming the exogenous KE, BD-AcAc, had lower age-related gains in body weight and FM compared to CON mice. Furthermore, transcriptional and proteomics data suggest a signature in skeletal muscle of KE-treated mice consistent with markers of improved skeletal muscle regeneration, improved electron transport chain utilization, and increased insulin sensitivity.
  • ||||||||||  Preclinical, Journal:  The roles of sclerostin and irisin on bone and muscle of orchiectomized rats. (Pubmed Central) -  Dec 2, 2022   
    Reduced BMD, impaired bone microarchitecture, weak strength of bone and muscle, and thin myofibers were induced by androgen deficiency of ORX rats. Serum sclerostin and irisin levels were significantly changed after ORX, which might be closely correlated with the occurrence of osteoporosis and sarcopenia in ORX rats.
  • ||||||||||  bardoxolone methyl (RTA 402) / Kyowa Kirin, Reata
    Journal:  Oxidized Albumin: Evaluation of Oxidative Stress as a Marker for the Progression of Kidney Disease. (Pubmed Central) -  Dec 1, 2022   
    Bardoxolone methyl, a nuclear factor-erythroid 2-related factor 2 (Nrf2) activator with anti-oxidative and inflammatory modulation effects, has been reported to improve renal function in clinical trials...Oxidized albumin is not only a marker for kidney disease but also a nephrotoxic substance. This suggests that measuring the levels of oxidized albumin could be a biomarker for diagnosing the progression of and complications associated with renal disease in addition to evaluating the efficacy of therapeutic drugs.
  • ||||||||||  Review, Journal:  Prevention of post-tips hepatic encephalopathy: The search of the ideal candidate. (Pubmed Central) -  Nov 30, 2022   
    However, the shunt of the portal blood into the systemic circulation is the cause of one of the major complications of the procedure: the post-TIPS hepatic encephalopathy (HE). To date, few pharmacological treatment has been proven effective to prevent this complication and thus, the identification of patients at high risk of post-TIPS hepatic encephalopathy and the patients' carefully selection is the only way to prevent this frequent complication.